ClinicalTrials.gg

Program

WRN Inhibitor AMG 436

Its studies are mostly in Neoplasm Metastasis, led by Amgen.

Furthest: phase 1, since Feb 5, 20261 company-led study, 1 open or runningNext primary completion: Jan 1, 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen11 open or runningphase 1since Feb 5, 2026Feb 5, 2026Jan 1, 2030phase 1 · NCT07403721

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 5, 2026First study: phase 1 study in Neoplasm MetastasisFirst studyNCT07403721 · 464 planned · United States, Australia, Belgium and more

Ahead

  1. Jan 1, 2030Primary completion: phase 1 study in Neoplasm MetastasisNCT07403721

TargetBeta

WRN →read by rule
“A selective inhibitor of the Werner syndrome ATP-dependent helicase (WRN), ”NCIt, by rule

Other programs on WRN

ProgramCompanyFurthest phaseStudies
WRN Inhibitor RO7589831ruleBayerphase 22
WRN Inhibitor GSK4418959ruleGlaxoSmithKlinephase 21
WRN Inhibitor NDI-219216rulenimbus-wadjet-incphase 21
WRN Inhibitor EIK1005ruleeikon-therapeuticsphase 21
WRN Inhibitor MOMA-341rulemoma-therapeuticsphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07403721Neoplasm Metastasis · United States, Australia, Belgium and more1RecruitingJan 1, 2030464

How it is read

Names in the registry

  • “AMG 436”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.